Efficacy and safety of ramucirumab treatment in patients with advanced colorectal cancer
A protocol for systematic review and meta analysis

Man Ju, MDa, Honggang Cheng, MDb, Kai Qu, MDc, Xiangqian Lu, MDd,e,*

Abstract
Background: vascular endothelial growth factor receptor 2 (VEGFR-2) has an important role in colorectal cancer pathogenesis and progression. The aim of our study is to provide a protocol for assessing the efficacy and safety of ramucirumab (a monoclonal antibody VEGFR-2 antagonist) for the treatment of advanced colorectal cancer.

Methods: The systematic review will be reported according to the preferred reporting items for systematic reviews and meta-analyses protocols. Relevant randomized controlled trials were searched from PubMed, Cochrane Library, Web of Science, Excerpt Medica Database, China National Knowledge Infrastructure, and Wanfang Database. Papers in English or Chinese published from their inception to February 2020 will be included without any restrictions.

Study selection and data extraction will be performed independently by 2 investigators. The clinical outcomes including overall response rate, complete response rate (disease control rate), overall survival, progression-free survival, quality of life, immune function, and adverse events, were systematically evaluated. Review Manager 5.3 and Stata 14.0 were used for data analysis, and a fixed or random-effect model of meta-analysis will be used depending upon the heterogeneity observed between studies. Subgroup analysis will be carried out depending on the availability of sufficient clinical data.

Results and Conclusion: The findings of this systematic review and meta-analysis will be published in a peer-reviewed journal, and provide more evidence-based guidance in clinical practice.

PROSPERO registration number: CRD42020165683.

Abbreviations: CC = colon cancer, CRC = colorectal cancer, OS = overall survival, PFS = progression-free survival, RC = rectal cancer, RCTs = randomized controlled trials.

Keywords: colorectal cancer, efficacy, meta-analysis, ramucirumab, safety

1. Introduction
Colorectal cancer (CRC) is the second most frequent cause of cancer-related death and caused 861,700 deaths worldwide in 2018.[1,2] In recent years, the incidence of CRC has significantly raised with about 1.8 million new cases every year. [1,2] CRC is often diagnosed in an advanced stage due to hiding of clinical symptom.[3] It is demonstrated that approximately 25% of CRC patients with metastases are diagnosed initially and nearly 50% of them will develop metastases afterwards.[3,4] Patients with metastatic disease have a poor prognosis with a 5-year survival rate of only 13.1%. [4] Surgery, radiotherapy and chemotherapy are the most widely used therapeutic methods for CRC. [5] However, many researchers reported that these conventional treatments was not able to completely eradicate small lesions and metastatic cells, which may raise the probability of cancer recurrence.[5] Thus, more effective and safer treatments were urgently required.[6–7]

Angiogenesis plays a central role in tumor growth and metastasis.[4,8] Tumors require a vascular supply to grow that is achieved via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands.[4,9] Tumor progression and poor prognosis in numerous tumor types, including CRC, has been associated with the overexpression of VEGF. VEGF ligands mediate their angiogenic effects via several different receptors.[4,10] VEGFR2, expressing in vessel endothelial cells, is the main receptor for the angiogenesis and responsible for proliferation, migration of endothelial cells.[4] Preclinical studies have demonstrated that blockade of the VEGF-A/vascular endothelial growth factor receptor 2 (VEGFR-2) interaction...
inhibits tumor angiogenesis and growth, rendering it a promising approach in anticancer treatments.\(^{11}\) Ramucirumab (Cyramza; IMC-1121B; LY3009806; Lilly Oncology) is a fully humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the VEGFR-2 extracellular domain, blocking all VEGF ligands from binding to this therapeutically validated target.\(^{12-14}\) As such, ramucirumab has the potential capacity to inhibit multiple activities initiated by VEGF activation of VEGFR-2.\(^{12-14}\)

Due to the improvement of overall survival (OS) and progression free survival (PFS) reported by the phase II/III clinical trial, ramucirumab treatment has been widely explored in the treatment of solid tumors,\(^{12,15,17-19}\) and approved by the US Food and Drug Administration for the treatment metastatic CRC in 2015.\(^{12}\) Many studies showed an obvious advantage for ramucirumab combined with conventional medicines in both OS and PFS of metastatic CRC patients.\(^{14,12}\) Despite the intensive clinical studies, its clinical efficacy was still not systematically evaluated. We are prepared to summarize the efficacy and adverse events of ramucirumab treatment of CRC at advanced stages through the meta-analysis, in order to provide scientific reference for the design of future clinical trials.

2. Study aim

The aim of this meta-analysis was to systematically evaluate the efficacy and safety of ramucirumab mediated therapy for the treatment of advanced CRC.

3. Methods

The protocol of our meta-analysis will be reported according to preferred reporting item for systematic review and meta-analysis protocols guidelines.\(^{20}\) Our protocol has been registered on the International Prospective Register of Systematic Review. The registration number was CRD42020165683 (Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020165683). This meta-analysis is a secondary research based on some previously published data. Therefore, the ethical approval or informed consent was not required in this study.

3.1. Data sources

Six electronic databases including Cochrane Library, Web of Science, PubMed, Excerpt Medica Database, China National Knowledge Infrastructure, and Wanfang Database will be systematically searched for eligible studies from their inception to February 2020. Language is limited with English and Chinese.

3.2. Search strategy

To perform a comprehensive and focused search, experienced systematic review researchers will be invited to develop a search strategy. The plan searched terms are as follows: “colorectal cancer” or “colorectal neoplasm” or “colorectal carcinoma” or “colorectal tumor” or “colon cancer” or “colon neoplasm” or “colon carcinoma” or “colon tumor” or “rectal cancer” or “rectal neoplasm” or “rectal carcinoma” or “rectal tumor” or “CRC” or “CC” or “RC” and “ramucirumab” or “IMC1121B” or “LY3009806” or “Cyramza” et al. An example of search strategy for PubMed database shown in Table 1 will be modified and used for the other databases.

3.3. Eligibility criteria

3.3.1. Types of studies. All available randomized controlled trials (RCTs) that investigated the efficacy and safety of ramucirumab treatment in patients diagnosed with advanced CRC will be included in this systematic review. Articles without sufficient available data, noncomparative studies, non-RCTs, literature reviews, meta-analysis, meeting abstracts, and case reports will be excluded.

3.3.2. Participants. Patients must be cytologically or pathologically confirmed as having CRC at a clinically advanced stage. There will be no limitations on age, gender, racial and region. Patients with other malignancies or nonprimary CRC are not included.

3.3.3. Interventions. CRC patients treated with conventional medicines and ramucirumab targeted therapy will be included. The dose and administered frequency of ramucirumab are not restricted.

3.3.4. Comparisons. CRC patient treated with the same conventional medicine as intervention group in the same original study.

3.3.5. Language. Studies published in English and Chinese will be included.

3.4. Outcomes

3.4.1. Primary outcomes. The primary outcomes will be the therapeutic effects of treatment according to Response Evaluation Criteria in Solid Tumors 1.1.\(^{21}\)

| Table 1 |
| --- |
| Searching strategy in PubMed. |
| **Search Strategy** |
| \#1. “colorectal cancer” or “colorectal neoplasm” or “colorectal carcinoma” or “colorectal tumor” or “colon cancer” or “colon neoplasm” or “colon carcinoma” or “colon tumor” or “rectal cancer” or “rectal neoplasm” or “rectal carcinoma” or “rectal tumor” or “CRC” or “CC” or “RC” [Title/Abstract]. |
| \#2. “colorectal cancer” or “colon cancer” or “rectal cancer” [MeSH]. |
| \#3. \#1 or \#2. |
| \#4. “ramucirumab” or “IMC1121B” or “LY3009806” or “Cyramza” or “vascular endothelial growth factor receptor 2” or “VEGFR-2” or “VEGFR-2 antagonist” or “angiogenesis inhibitors” [Title/Abstract]. |
| \#5. \#3 and \#4. |
| \#6. limit \#5 to human. |
| \#7. limit \#6 to “Randomized controlled clinical trial” [Publication Type]. |
| \#8. limit \#7 to yr=“-February 2020.” |
3.4.2. *Secondary outcomes.* Secondary outcomes will include:

1. Immune function evaluation;
2. Quality of life as evaluated by Karnofsky score, and
3. Treatment-related adverse effects assessment.

3.4.3. *Outcome follow-up periods.* Early and durable response will be recorded among included studies. All time points will be considered due to the anticipated variability in follow-up. The details of the follow-up period will also be recorded for all studies.

3.5. *Study selection and management*

Endnote X7 software will be used for literature managing and records searching. Two authors (Ju M and Cheng HG) will be reviewed independently to identify potential trials by assessing the titles and abstracts. The full text of all relevant trials will be further evaluated to make sure eligible trials. Any conflict will be resolved through discussion with a third reviewer (Qu K). A preferred reporting items for systematic review and meta-analysis-compliant flow diagram (Fig. 1) will be used to describe the selection process of eligible literatures.

3.6. *Data extraction and management*

Two reviewers (Ju M and Cheng HG) will be responsible for the data extraction independently according to the Cochrane Handbook for Systematic Reviews of Intervention. The following data will be extracted from eligible literatures: the first author, year of publication, country of study, participants (sample size, tumor-node-metastasis stage, age, gender, inclusion and exclusion criteria, etc), details of all experimental and control interventions regimen (dosage of ramucirumab, administration route, duration of treatment, follow-up time, etc), outcomes (overall response rate, disease control rate, OS, PFS, quality of life, immune function and adverse effects). For survival outcomes,
Hazard ratios with corresponding 95% confidence intervals will be extracted from trials or be estimated from Kaplan–Meier survival curves by established methods. Any disagreements will be resolved by discussion, and a third reviewer (Qu K) will make the final decision. Excluded studies and the reasons for exclusion will be listed in a table.

3.7. Dealing with missing data
We will attempt to contact the authors to request the missing or incomplete data. If those relevant data are not acquired, they will be excluded from the analysis.

3.8. Risk of bias of individual study
The quality of the included RCTs will be assessed independently by 2 investigators (Ju M and Cheng HG) in terms of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias, according to the guidance of the Cochrane Handbook for Systematic Review of Interventions. Evidence quality will be classified as low risk, high risk, or unclear risk of bias in accordance with the criteria of the risk of bias judgment. Any disagreements will be resolved via discussion with a third researcher (Qu K).

3.9. Data synthesis
Statistical analyses will be performed using Review Manager 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) and Stata 14.0 (Stata Corp., College Station, TX) statistical software. The outcomes were mainly represented by risk ratio with its 95% confidence intervals. A 2-tailed P-value <.05 was considered statistically significant. Cochrane Q-test and I² statistics were used to assess heterogeneity between studies; P < .1 or I² > 50% indicates statistical heterogeneity. A fixed effect model will be used to calculate the outcomes when statistical heterogeneity is absent; otherwise, the random effects model was considered according to the DerSimonian and Laird method.

3.10. Publication bias analyses
We will detect publication biases and poor methodological quality of studies using funnel plots if 10 or more studies are included in the meta-analysis. Begg and Egger regression test will be utilized to detect the funnel plot asymmetry. If publication bias existed, a trim-and-fill method should be applied to coordinate the estimates from unpublished studies, and the adjusted results were compared with the original pooled RR.

3.11. Assessment of heterogeneity
3.11.1. Sensitivity analysis. Sensitivity analysis was conducted to explore an individual study’s influence on the pooled results by deleting 1 single study each time from pooled analysis. A summary table will report the results of the sensitivity analyses.

3.11.2. Subgroup and meta-regression analysis. If the data are available and sufficient, subgroup and meta-regression analysis will be conducted to explore the source of heterogeneity with respect to age, gender, region, tumor stage, sample sizes, follow-up period, chemotherapy regimens, and types of involved studies.

3.12. Dissemination plans
We will disseminate the results of this systematic review by publishing the manuscript in a peer-reviewed journal or presenting the findings at a relevant conference.

4. Discussion
Current treatment methods for CRC only have a modest survival benefit. With the development and clinical application of molecule-targeted drugs, the molecule-targeted treatment of tumors has been widely accepted. The agents used in targeted therapy can precisely identify and attack certain type of cancer cells based on mutations of genes and proteins, with little damage for normal cells. As an effective molecule-targeted agent, ramucirumab has been widely used for the treatment of diverse malignant tumors worldwide.

4.1. Strengths and limitations of this study
Even though there was statistical analysis of published clinical trials, the exact therapeutic effects of ramucirumab treatment were still not systematically investigated. This systematic review may provide helpful evidence for clinicians, and patients who use ramucirumab for the treatment of advanced CRC. The systematic review will also have some limitations. There may be a language bias with the limitation of English and Chinese studies. Clinical heterogeneity may exist for different tumor stage and ages of CRC patients, dosage of ramucirumab, and duration of treatment.

Author contributions
Conceptualization: Xiangqian Lu and Kai Qu.
Investigation: Xiangqian Lu, Man Ju, and Honggang Cheng.
Methodology: Xiangqian Lu, Man Ju, and Honggang Cheng.
Project administration: Xiangqian Lu.
Supervision: Xiangqian Lu and Kai Qu.
Funding acquisition: Kai Qu.
Writing – original draft: Man Ju and Honggang Cheng.
Writing – review and editing: Xiangqian Lu and Man Ju.

References
[1] Ferlay J, Colombo M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[3] Jiang Y, Fan H, Song G, et al. Efficacy and safety of FOLFIRI and bevacizumab versus FOLFOXIRI alone for metastatic colorectal cancer patients: a meta-analysis. Medicine 2017;96:e8767.
[4] Verduguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol 2016;8:230–42.
[5] Zhang L, Mu Y, Zhang A, et al. Cytokine-induced killer cells/dendritic cells–cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients. Oncotarget 2017;8:45164–77.
[6] Advani S, Kopetz S. Ongoing and future directions in the management of metastatic colorectal cancer: update on clinical trials. J Surg Oncol 2019;119:642–52.
[7] Martini G, Troiani T, Cardone C, et al. Present and future of metastatic colorectal cancer treatment: a review of new candidate targets. World J Gastroenterol 2017;23:4675–88.
[8] Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer. Cancer J 2018;24:165–70.

[9] Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643–51.

[10] Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748–53.

[11] Zhu Z, Bohlen P, Witt L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002;2:133–56.

[12] Wang K, Xu X, Wang Y, et al. The impact of ramucirumab on survival in patients with advanced solid tumors: a systematic review and meta-analysis of randomized IBIII controlled trials. Clin Drug Invest 2016;36:27–39.

[13] Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013;13:1187–96.

[14] Lopez A, Harada K, Vasilakopoulou M, et al. Targeting angiogenesis in colorectal carcinoma. Drugs 2019;79:63–74.

[15] Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2014;13:1224–35.

[16] Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–35.

[17] Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab plus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859–70.

[18] Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol 2019;30:2016.

[19] Yoshihara T, Kusaba H, Makiyama A, et al. Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. Int J Clin Oncol 2019;24:508–15.

[20] Shamser L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.

[21] Schwartz LH, Littare S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 2016;62:132–7.

[22] Tierney JF, Stewart LA, Gheusi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.

[23] Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015;8:2–10.

[24] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[25] Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012;31:3805–20.

[26] George BJ, Aban IB. An application of meta-analysis based on DerSimonian and Laird method. J Nucl Cardiol 2016;23:690–2.

[27] Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics 2018;74:785–94.

[28] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.

[29] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[30] Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine 2019;98:e15987.

[31] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.

[32] Cheng H, Sun A, Guo Q, et al. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis. Drug Des Devel Ther 2018;12:2173–83.

[33] Geng F, Wang Z, Yin H, et al. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives. Cancer Biother Radiopharm 2017;32:149–60.

[34] Seebor A, Gaul G. Targeted therapy of colorectal cancer. Oncol Res Treat 2016;39:796–802.

[35] Xie YH, Chen XY, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22.